Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Index
-
Market Cap
6.10B
Enterprise Value
10.96B
Income
-219.00M
Sales
5.21B
Book/sh
17.90
Cash/sh
0.78
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
13000
IPO
May 06, 2022
P/E
-
Forward P/E
16.02
PEG
0.41
P/S
1.17
P/B
0.96
P/C
21.87
P/FCF
7093.42
EV/EBITDA
15.14
EV/Sales
2.11
Quick Ratio
0.99
Current Ratio
1.53
Debt/Eq
0.79
LT Debt/Eq
0.79
Option/Short
Yes / Yes
EPS (ttm)
-0.62
EPS next Y
1.07
EPS next Q
0.15
EPS this Y
58.20%
EPS next Y
32.34%
EPS next 5Y
39.39%
EPS past 3/5Y
- -
Sales past 3/5Y
10.62% 8.38%
EPS Y/Y TTM
39.85%
Sales Y/Y TTM
7.85%
EPS Q/Q
66.73%
Sales Q/Q
9.41%
Insider Own
88.85%
Insider Trans
0.02%
Inst Own
9.98%
Inst Trans
-1.09%
ROA
-1.61%
ROE
-3.44%
ROIC
-1.92%
Gross Margin
55.86%
Oper. Margin
5.91%
Profit Margin
-4.21%
SMA20
9.13%
SMA50
8.39%
SMA200
5.66%
Trades
Shs Outstand
356.40M
Shs Float
39.77M
52W High
18.92 -9.54%
52W Low
13.09 30.71%
Volatility
2.58% 2.76%
ATR (14)
0.44
RSI (14)
71.85
Beta
0.56
Rel Volume
0.81
Avg Volume
445.41K
Volume
359,749
Perf Week
4.84%
Perf Month
15.06%
Perf Quarter
3.76%
Perf Half Y
0.18%
Perf YTD
0.18%
Perf Year
23.27%
Perf 3Y
-12.79%
Perf 5Y
-
Perf 10Y
-
Prev Close
17.16
Price
17.11
Change
-0.29%
Date Action Analyst Rating Change Price Target Change
Jan-05-26Downgrade Evercore ISI Outperform → In-line $18
Dec-11-25Upgrade Citigroup Neutral → Buy $20
Dec-02-25Upgrade Morgan Stanley Equal-Weight → Overweight $21
Oct-01-25Initiated Goldman Neutral $16
May-02-25Reiterated H.C. Wainwright Buy $20 → $15
Mar-28-25Downgrade Wells Fargo Overweight → Equal Weight $24 → $15
Dec-11-24Downgrade Citigroup Buy → Neutral $24 → $22
Dec-02-24Downgrade Morgan Stanley Overweight → Equal-Weight $19
Oct-15-24Upgrade Evercore ISI In-line → Outperform $19 → $25
Jul-10-24Initiated Raymond James Outperform $19
Jul-06-26 07:15AM
Jul-01-26 07:00AM
Jun-10-26 06:00AM
05:12AM
Jun-01-26 06:59AM
07:15AM Loading…
May-21-26 07:15AM
May-20-26 04:49PM
May-19-26 07:00AM
May-07-26 07:00AM
May-06-26 07:15AM
Apr-30-26 08:30AM
07:00AM
03:18AM
Apr-29-26 07:07AM
06:58AM
07:00AM Loading…
Apr-23-26 07:00AM
Apr-22-26 07:15AM
Apr-16-26 07:00AM
Apr-08-26 07:00AM
Apr-07-26 07:00AM
Apr-06-26 07:00AM
Mar-30-26 07:15AM
Mar-23-26 07:00AM
Mar-11-26 06:00AM
Mar-09-26 07:15AM
Feb-27-26 12:57PM
05:14AM
Feb-25-26 12:36AM
Feb-24-26 07:00AM
Feb-19-26 12:00PM
12:31AM Loading…
12:31AM
Feb-18-26 10:11PM
04:31PM
02:58PM
02:23PM
02:00PM
01:25PM
01:25PM
09:36AM
09:30AM
08:10AM
07:37AM
07:19AM
06:58AM
Feb-16-26 10:07PM
09:15AM
Feb-12-26 08:50AM
Feb-11-26 09:30AM
Feb-09-26 11:02PM
11:40AM
Jan-29-26 11:34PM
Jan-23-26 11:40AM
Jan-20-26 07:15AM
Jan-05-26 07:00AM
Jan-02-26 04:30PM
Dec-23-25 07:30AM
Dec-17-25 04:30PM
Dec-12-25 04:48PM
Dec-11-25 11:41AM
Dec-04-25 10:09PM
Dec-02-25 11:10AM
Nov-18-25 04:30PM
Nov-13-25 02:57PM
08:55AM
08:41AM
Nov-10-25 06:59AM
04:28AM
Nov-05-25 12:35AM
Nov-03-25 04:30PM
Oct-30-25 01:34AM
Oct-29-25 03:47PM
09:30AM
08:05AM
07:23AM
07:06AM
06:58AM
Oct-28-25 09:26AM
Oct-27-25 11:12PM
Oct-20-25 06:44PM
11:36AM
09:34AM
07:41AM
07:25AM
Oct-19-25 08:00PM
Oct-17-25 12:24PM
Oct-10-25 06:44PM
Oct-02-25 11:40AM
Oct-01-25 11:01AM
Sep-25-25 01:06PM
Sep-11-25 07:00AM
Sep-09-25 07:00AM
Sep-08-25 06:56PM
04:30PM
07:00AM
Sep-05-25 12:41AM
Aug-22-25 02:25PM
Aug-20-25 11:31PM
Aug-18-25 05:48PM
05:01PM
Aug-14-25 07:15AM
Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company operates its business through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals and Surgical. The Vision Care/Consumer Health Care segment includes both contact lens and consumer eye care businesses. The Ophthalmic Pharmaceuticals segment consists of a broad line of proprietary pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. The Surgical segment consists of medical device equipment, consumables and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions, and includes IOLs and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. Bausch + Lomb was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Vaughan, Canada.
CEO & ChairmanMr. Brenton L. Saunders J.D.
Executive VP & CFOMr. Osama A. Eldessouky
Executive VP & Chief Legal OfficerMr. A. Robert D. Bailey
Ph.D.Dr. Yehia Hashad M.D.
President of Global Pharmaceuticals & International ConsumerMr. Andrew J. Stewart
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bailey A Robert DEVP & Chief Legal OfficerMar 06 '26Buy17.1514,600250,332231,890Mar 10 05:23 PM
Eldessouky SamEVP and CFOMar 06 '26Buy17.134,00068,520403,130Mar 10 04:34 PM
SAUNDERS BRENT LCEO and Chairman of the BoardMar 06 '26Buy17.1414,700251,958966,575Mar 10 04:32 PM
Ross Thomas W. Sr.DirectorMar 03 '26Buy17.684,50079,55664,891Mar 04 04:18 PM
Alfonso EduardoDirectorMar 02 '26Buy17.904,30076,9709,555Mar 03 04:26 PM
VON ESCHENBACH ANDREW C.DirectorFeb 27 '26Buy18.304,36479,88366,450Mar 03 04:24 PM
COLLIS STEVEN HDirectorFeb 23 '26Buy17.8115,000267,15020,255Feb 24 04:23 PM
ROBERTSON RUSSEL CDirectorFeb 20 '26Buy17.904,40078,76072,407Feb 24 04:16 PM
Ling KarenDirectorFeb 19 '26Buy17.744,00070,96841,676Feb 23 04:20 PM